Lantheus Holdings, Inc. is 3.8x more valuable than Intellia Therapeutics, Inc. by market capitalization ($6.53 B vs $1.70 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | LNTH | NTLA |
|---|---|---|
| Market cap | $6.53 B | $1.70 B |
| US-listed rank | #1201 | #2215 |
| Revenue (latest FY) | $1.54B | $67.67M |
| Net income (latest FY) | $233.56M | -$412.69M |
| Net margin | 15.2% | -609.9% |
| P/E (trailing FY) | 27.9 | - |
| SEC filings | 1,079 | 687 |
Lantheus Holdings, Inc. is 3.8x more valuable than Intellia Therapeutics, Inc. by market capitalization ($6.53 B vs $1.70 B).
In their latest fiscal years, Lantheus Holdings, Inc. reported $1.54B in revenue while Intellia Therapeutics, Inc. reported $67.67M.
Full pages: Lantheus Holdings, Inc. and Intellia Therapeutics, Inc., or browse the full rankings.